Medeniyet medical journal最新文献

Objective: Gastric cancer remains a significant global health concern, necessitating investigation into more effective treatment approaches. This study investigates the combined effects of rosmarinic acid, a polyphenolic compound with known anticancer properties, and cisplatin, a conventional chemotherapeutic agent, on human gastric carcinoma (HGC-27) cells.

Methods: Cell viability was evaluated at different concentrations for rosmarinic acid and cisplatin, and inhibitory concentration (IC)50, IC30, and IC10 values were subsequently determined. IC30 and IC10 doses were selected for combination experiments. Thiazolyl Blue Tetrazolium Bromide assay, colony formation assay, in vitro scratch assay, and 3D tumor spheroid growth assay were performed to evaluate the effects of individual and combined treatments.

Results: Rosmarinic acid and cisplatin individually reduced cell viability in a dose-dependent manner. Both the IC10 and IC30 dose combinations of the two agents demonstrated significant inhibitory effects on colony formation and cell motility, indicating an additive interaction compared with the control and the individual treatments. The combined treatment also inhibited spheroid growth, although the extent of the reduction was similar to that observed with the individual agents.

Conclusions: This study provides initial insights into the potential efficacy of the rosmarinic acid-cisplatin combination. The combination of these agents reduced cell viability, colony formation, and cell motility. The increased cytotoxicity observed in 2D models was not evident in 3D spheroid models, highlighting the importance of 3D systems that more accurately mimic the complex structure of tumors. This finding suggests that differences in drug sensitivity between 2D and 3D models should be considered when evaluating combination therapies.

Objective: Supine percutaneous nephrolithotomy (sPCNL) is widely accepted as a safe and effective treatment for kidney stones. This study aims to assess surgical outcomes and identify predictive factors for residual fragments following sPCNL in the Galdakao-modified Valdivia position (GMV-sPCNL).

Methods: We retrospectively evaluated the clinical data of patients undergoing GMV-sPCNL. The primary outcomes were the stone-free rate (SFR) and the complication rate. Demographic, radiologic, and perioperative parameters were also compared between patients with and without residual stones.

Results: 195 patients [Male:127 (65.1%); Female: 68 (34.9%)] were included. The mean age was 48.6±15.6 years; the mean body mass index (BMI) was 27.4±5 kg/m2. The overall SFR was 83.1%. Residual stones were associated with greater stone burden (number, size, surface area, and volume), longer operative time, and longer hospitalization (p<0.05). Gender, age, BMI, stone laterality, and density were not significantly associated with SFR. The receiver operating characteristic analysis showed that having more than two stones, a stone size ≥26 mm, or a stone volume ≥2639.8 mm3 significantly predicted residual fragments. Stone volume demonstrated the best predictive performance, with sensitivity and specificity of 81.8% and 61.0%, respectively. GMV-sPCNL was associated with a low overall complication rate: 86.2% of patients experienced no or only minor complications, and major complications (Clavien-Dindo ≥3) occurred in just 4.6% of cases.

Conclusions: GMV-sPCNL demonstrates high success rates and an acceptable complication profile. Stone burden parameters such as stone number, stone size, and stone volume are important determinants of surgical success.

Objective: This study aimed to evaluate long-term skin histomorphometry at 18 months postpartum in rats exposed in utero to 3.5 GHz radiofrequency radiation (RFR).

Methods: Pregnant Wistar Hannover rats were exposed to Global System for Mobile Communications-modulated 3.5 GHz RFR for 2 h/day throughout gestation, while the sham group underwent mock exposure. Offspring (n=5 per group) were not exposed to any further RFR until 18 months after birth. Dorsal skin samples were stained with hematoxylin-eosin and Masson's trichrome, and dermal thickness, adipose tissue area, dermal area, adipose/dermis ratio, and fat percentage were quantified. Specific absorption rate (SAR) was calculated using CST Studio Suite. Data were analyzed using the Student's t-test or the Mann-Whitney U test. Statistical significance was defined as p<0.05.

Results: The peak spatial SAR (psSAR) values were 0.06622 mW/g (for 1 g) and 0.03825 mW/g (for 10 g). No statistically significant differences were observed between RFR-exposed and sham groups in dermal thickness (655.32±87.46 μm vs 544.42±135.01 μm); fat area percentage (0.73±0.29% vs 0.66±0.22%); dermal area (1.05±0.17 vs 0.88±0.22); adipose/dermis ratio (1.78 ± 0.24 vs 1.54±0.28); or fat percentage (40.04±11.78% vs 42.96±11.60%) (all p>0.05).

Conclusions: Prenatal exposure to 3.5 GHz RFR did not cause significant skin histomorphometric alterations in the dermis of aged female rats. The skin's barrier properties, regenerative capacity, and repair mechanisms may mitigate long-term structural effects of such exposures.

Objective: Sleep is vital for homeostasis. Smoking negatively affects sleep quality, whereas regular physical activity and reduced sedentary behavior improve sleep quality. However, the combined effect of e-cigarettes, physical activity, and sedentary behavior remains unknown. Therefore, the current study compared sleep quality according to e-cigarette dependence status among adults with high versus low levels of physical activity and sedentary behavior.

Methods: In 644 adults, sleep, e-cigarette dependence, physical activity, and sedentary behavior were assessed using the Pittsburgh Sleep Quality Index (PSQI), the Penn State E-Cigarette Dependence Index, and the International Physical Activity Questionnaire, respectively.

Results: The two-way ANCOVA, after controlling for gender, income, and disease status, revealed main effects of e-cigarette dependence (p<0.001) and sedentary behavior (p<0.03), and an interaction effect (p<0.05) on the PSQI. Post hoc comparisons showed significantly greater PSQI scores among adults with heavy e-cigarette dependence and in the high sedentary behavior group (p<0.05). However, the analysis showed no main effect of physical activity on PSQI scores (p>0.05).

Conclusions: The results suggest that heavy dependence on e-cigarettes negatively alters sleep quality. These adverse sleep alterations are exacerbated by sedentary behavior. Programs are needed to reduce e-cigarette use and sedentary behavior to enhance sleep quality.

Objective: To compare mechanical power (MP) levels among flow-controlled ventilation (FCV), volume-controlled ventilation (VCV), and pressure-controlled volume-guaranteed ventilation (PCV-VG) during laparoscopic surgery and to test the hypothesis that the stable flow dynamics of FCV would reduce MP.

Methods: Patients were divided into three groups according to the mechanical ventilation modes applied during laparoscopic surgery: PCV-VG (n=15), VCV (n=14), and FCV (n=15). MP was calculated at four timepoints: baseline (T1), post-induction (T2), during CO₂ insufflation (T3), and post-insufflation (T4). The primary outcome of the study was the comparison of MP in the FCV mode with MP in the other groups during insufflation. Driving pressure (DP), plateau pressure, and peak airway pressure were also analyzed.

Results: Baseline MP was highest in PCV-VG (6.9 J/min vs. 5.0 J/min in VCV and 5.1 J/min in FCV; p=0.002). During insufflation (T3), MP increased to a similar extent across groups (PCV-VG: 9.4 J/min, VCV: 8.7 J/min, FCV: 8.6 J/min), with PCV-VG showing the smallest relative rise (p<0.001). DP and plateau pressures increased during pneumoperitoneum, but Bonferroni-adjusted comparisons revealed that these were not statistically significant. PCV-VG maintained higher positive end-expiratory pressure (5 vs. 4 cmH₂O, p<0.001); however, it did not significantly affect peak pressures.

Conclusions: Contrary to our hypothesis, FCV did not reduce MP more effectively than either VCV or PCV-VG. However, PCV-VG demonstrated better mitigation of insufflation-induced increases in MP, suggesting potential advantages for lung protection during laparoscopy. Further prospective studies are needed to assess clinical outcomes.

Objective: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia in patients with chronic kidney disease. We aimed to assess its safety and tolerability profile through a meta-analysis of randomized controlled trials (RCTs).

Methods: A systematic search of the Cochrane CENTRAL, Ovid Medline R, PubMed, and Web of Science databases was conducted up to January 1, 2025 was conducted. RCTs comparing roxadustat with control groups were included. Inverse-variance-weighted random-effects models were used. The primary outcome was the risk of any serious treatment-emergent adverse event (TEAE). Subgroup analyses were based on etiology, comparator, and prior erythropoiesis-stimulating agent (ESA) use.

Results: Twenty-one RCTs involving 11.686 patients were included. Roxadustat was not associated with a higher risk of any serious TEAE compared with placebo [risk ratio (RR) =1.37, 95% confidence interval (CI): 0.79-2.37] or with ESA (RR=1.05, 95% CI: 0.99-1.10). Similarly, cardiac serious adverse events (SAEs) did not differ significantly when compared with ESA (RR=1.11, 95% CI: 0.75-1.12) or placebo (RR=1.11, 95% CI: 0.92-1.35). Hyperkalemia incidence was significantly higher compared with placebo (RR=1.25, 95% CI: 1.02-1.53) but not compared with ESA (RR=1.03, 95% CI: 0.77-1.36). There were also no significant differences in the incidence of serious infections (RR=0.74, 95% CI: 0.21-2.59), azotemia (RR=0.96, 95% CI: 0.46-2.00), hypertension (RR=1.06, 95% CI: 0.93-1.21), or pneumonia (RR=0.96, 95% CI: 0.81-1.14) compared with ESA. Notably, withdrawal due to adverse events (RR=2.11, 95% CI: 1.59-2.79) was significantly higher compared with ESA. TEAEs leading to death were similar compared with ESA (RR=0.98, 95% CI: 0.85-1.13) but were increased compared with placebo (RR=1.21, 95% CI: 1.04-1.42). All-cause mortality was significantly lower than with placebo (RR=0.40, 95% CI: 0.28-0.57) but was similar to ESA (RR=0.89, 95% CI: 0.57-1.37). Subgroup analyses for the primary outcome by etiology and prior ESA use were not consistent with the main findings.

Conclusions: Roxadustat demonstrated a SAE profile generally comparable to that of ESA, with no significant differences in cardiac SAEs, serious infections, azotemia, hypertension, or pneumonia. Hyperkalemia was more frequent compared with placebo, and withdrawals due to adverse events were more frequent compared with ESA. TEAEs leading to death were similar to ESA but higher than with placebo, whereas all-cause mortality was lower than with placebo and comparable to ESA. Taken together, current evidence supports the overall non-inferiority of roxadustat to ESA in terms of safety.

Objectives: Multiple sclerosis (MS) is a complex autoimmune disease of the central nervous system for which reliable biomarkers of disease activity remain an unmet need. Interleukin-40 (IL-40) and soluble CD40 ligand (sCD40L) have been proposed to play roles in the pathogenesis of autoimmune diseases. This study aimed to evaluate serum levels of IL-40 and sCD40L as biomarkers of disease activity in MS patients, and to compare their diagnostic and monitoring performance between MS patients and healthy controls.

Methods: One hundred twenty MS patients were recruited from the Department of MS at the Baghdad Teaching Hospital and divided into two groups based on disease status: active (n=60) and inactive (n=60). Additionally, 57 matched healthy individuals were included as controls. A sandwich enzyme-linked immunosorbent assay was used to measure the serum levels of IL-40 and sCD40L in blood samples from each participant.

Results: Both active and inactive patient cohorts showed significantly higher serum levels of IL-40 (44.25±8.57 ng/mL and 38.98±11.31 ng/mL, respectively) compared with their control group (20.82±14.27 ng/mL) (p=0.005). Likewise, sCD40L concentrations were elevated in both active (2155.59±587.02 pg/mL) and inactive (1885.23±851.32 pg/mL) patients compared with controls (849.79±341.87 pg/mL; p=0.0006). IL-40 correlated positively with sCD40L (r=0.399, p=0.005). The receiver operating characteristic analysis showed high diagnostic performance for IL-40 (area under the curve =0.873; sensitivity 87.5%; specificity 76.7%) and sCD40L (area under the curve =0.901; sensitivity 92.5%; specificity 81.7%).

Conclusions: Both IL-40 and sCD40L are significantly elevated in MS and exhibit promising diagnostic validity. These biomarkers may serve as complementary tools for monitoring MS disease activity and progression, offering potential value in clinical practice and therapeutic decision-making.

Objective: Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are both severe autoimmune diseases characterised by immune dysregulation and systemic inflammation. Despite advances in diagnostic tools, distinguishing RA from SLE remains challenging due to overlapping clinical manifestations. Emerging evidence highlights the potential roles of novel cytokines, such as interleukin-39 [(IL)-39] and IL-40, in autoimmune pathogenesis. This study aimed to evaluate the diagnostic utility of serum levels of IL-39 and IL-40 for differentiating RA from SLE using several machine learning (ML) algorithms.

Methods: Data from 66 patients with RA and 66 patients with SLE were analysed using previously published serum IL-39 and IL-40 datasets. ML algorithms, namely logistic regression, random forest, decision tree, and support vector machine, were applied. Model performance was evaluated using sensitivity, accuracy, specificity, and area under the receiver operating characteristic curve.

Results: SLE patients exhibited significantly higher serum IL-39 and IL-40 levels than those of RA patients (p<0.001). The random forest model achieved an accuracy of 92.4% and an AUC of 0.95. Feature importance analysis revealed that IL-39 and IL-40 contributed 58% and 42%, respectively to the classification performance.

Conclusions: ML models based on IL-39 and IL-40 serum levels can effectively differentiate RA from SLE. The findings suggest that integrating artificial intelligence-based analytical approaches with novel cytokine biomarkers may enhance diagnostic precision and support differential diagnosis in autoimmune diseases.

Objective: Idiopathic nephrotic syndrome (NS) is a common pediatric glomerular disorder. Podocyte damage constitutes a central mechanism in its pathophysiology. Podocalyxin, a major sialoglycoprotein expressed on podocytes, has been found to be elevated in urine samples from patients with glomerular diseases. However, its potential role in serum and its association with steroid responsiveness in NS remain unexplored.

Methods: This observational study included 17 children diagnosed with NS and age-matched controls without kidney pathology. Serum podocalyxin levels were measured at diagnosis using enzyme-linked immunosorbent assay. Patients received standard corticosteroid therapy at a dose of 2 mg/kg/day for four weeks, followed by a gradual taper. Based on clinical response, patients were classified as steroid-sensitive or steroid-dependent NS (SDNS). Serum podocalyxin levels were compared between patients and controls, and among subgroups based on treatment response.

Results: Serum podocalyxin levels were significantly higher in NS than in the control group [1.87 ng/dL [interquartile range (IQR: 0.87)] vs. 1.54 ng/dL (IQR: 0.29), p=0.031]. All patients initially achieved remission with corticosteroids; however, six patients subsequently developed SDNS. Among these, 4 responded to calcineurin inhibitors, while 2 required rituximab to achieve remission. Current results indicate that serum podocalyxin levels do not provide sufficient predictive value for estimating steroid response or disease course. No significant correlations were found between podocalyxin levels and other laboratory parameters.

Conclusions: Serum podocalyxin levels are elevated in pediatric NS and may reflect the degree of podocyte injury. However, current findings indicate that serum podocalyxin levels are insufficient for predicting disease severity or steroid response. Additional studies involving larger patient cohorts are needed to further substantiate findings.